Stock Price & Analysis

Based on the provided data and recent developments, here's a comprehensive analysis of whether to buy or sell REGN stock:

Technical Analysis The stock has shown strong upward momentum recently, with the price rising from $878 to $981 over the past month. The RSI-14 at 52.55 indicates neutral momentum, while the MACD shows a positive trend with the histogram turning upward (MACD: -5.27, Signal: -8.24, Histogram: 2.97).

Recent Catalysts

1. Dividend Initiation: REGN recently announced its first-ever quarterly dividend of $0.88 per share, demonstrating financial strength and commitment to shareholder returns.

2. FDA Priority Review: Dupixent received FDA priority review for bullous pemphigoid treatment, with a decision expected by June 20, 2025.

3. Legal Challenge: A recent court ruling regarding kickback allegations may complicate the government's lawsuit against Regeneron's Eylea marketing practices.

Analyst Sentiment Leerink Partners recently upgraded REGN to outperform with a price target of $834, citing potential acceleration in financial growth by 2026. Of 28 analysts covering the stock, 18 rate it a buy or strong buy.

Conclusion SELL recommendation at current levels ($981.20) for the following reasons:

• Stock is trading near 52-week highs
• Current price exceeds most analyst targets
• Legal uncertainties around Eylea marketing practices
• Increasing competition in key drug markets

Consider re-entering at lower levels around $834-850 range where risk/reward becomes more favorable.

Based on the provided data and recent market developments, here's a comprehensive price prediction analysis for REGN stock in 2025:

Technical Analysis:

• Current price: $700.41 (Pre-market on Feb 24, 2025)
• Key resistance levels: $734.77 (Upper Bollinger Band)
• Key support levels: $638.47 (Lower Bollinger Band)
• RSI-14 at 52.55 indicates neutral momentum
• MACD shows potential bullish crossover with positive histogram

Fundamental Drivers:

• Strong Q4 2024 performance with revenue beating estimates at $3.79 billion
• New quarterly dividend program initiated at $0.88 per share
• Additional $3 billion share repurchase program announced
• Eylea HD showing promising growth with $305 million in Q4 2024 sales
• Libtayo sales grew 50% year-over-year to $367 million

Price Target Scenarios for 2025:

1. Bullish Case ($834-920): Supported by Leerink Partners' upgraded price target and Reddit analysis

• Driven by Dupixent revenue growth
• Pipeline advancement
• P/E multiple expansion
• Probability: 60%

2. Base Case ($750-800):

• Continued Eylea pressure but offset by other product growth
• Stable margins and buyback support
• Probability: 30%

3. Bearish Case ($640-700):

• Further Eylea competition
• Pipeline setbacks
• Market volatility
• Probability: 10%

Most likely scenario: The stock is expected to reach $834 by end of 2025, supported by:

• Strong product portfolio diversification
• Robust pipeline with 40 candidates
• Analyst consensus showing 37% upside potential
• New dividend program providing additional shareholder value

The S1 support level for REGN Stock is $662.38 ,The R1 resistant level for REGN Stock is $725.91.

As of the end of day on 2025-02-26, the price of REGN Stock was $727.49.

The target price for REGN Stock according to analyst rating is 958.60, with the highest price target at 1,182 and the lowest at 575.00. Analysts have a Strong Buy rating on REGN Stock overall.

The market cap of REGN is $79.1B.

Based on the provided data and recent market developments, here's a comprehensive analysis of REGN's valuation:

Technical Analysis

The stock shows a strong upward trend since January 2024, with current price around $981.20 (as of Feb 23, 2025). RSI at 52.55 indicates neutral momentum, while the stock trades above both its 60-day ($713.73) and 200-day ($933.23) moving averages.

Fundamental Valuation

The stock appears fairly valued considering:

• P/E ratio increased from 18.88x (2022) to 25.26x (2023)
• EV/EBITDA rose from 13.06x to 18.33x
• Price/Sales ratio at 7.61x vs 6.73x year-over-year
• Price/Book ratio slightly up at 3.70x from 3.49x

Recent Developments

• FDA granted Priority Review for Dupixent to treat bullous pemphigoid, with decision expected by June 2025
• Favorable court ruling regarding kickback lawsuit, making it harder for U.S. authorities to win their case
• Strong institutional interest with 613 institutions adding positions recently

Financial Health

• Revenue grew 7.8% YoY to $13.12B in 2023
• Net margin declined to 30.14% from 35.64%
• Strong balance sheet with current ratio of 5.69
• Low debt-to-equity ratio of 0.104

Conclusion

REGN appears slightly overvalued at current levels based on:

1. Elevated valuation multiples compared to historical averages
2. Declining margins despite revenue growth
3. Technical indicators suggesting overbought conditions

However, positive catalysts like the Dupixent expansion and favorable legal developments could support the valuation.

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others. The Company’s solid tumor and other oncology and autoimmune cell therapy programs include the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets.

Based on the available data and market analysis, here is the price prediction for REGN stock by 2030:

Regeneron Pharmaceuticals (REGN) is projected to reach $1,030-$1,150 by 2030, driven by continued growth in its Dupixent franchise and pipeline advancement, despite near-term Eylea sales pressure. The stock has faced recent headwinds with a 35% decline over six months due to Eylea competition and legal challenges, but analysts remain bullish with 18 out of 28 rating it a buy.

The company's strong fundamentals, including an 87% gross margin and 31% net margin, combined with its track record of innovation, support this long-term price target, though legal uncertainties around Eylea pricing could create volatility.

REGN has a total of 13450 employees.